» Articles » PMID: 31420888

Fertility Preservation in Turner Syndrome: Karyotype Does Not Predict Ovarian Response to Stimulation

Overview
Specialty Endocrinology
Date 2019 Aug 18
PMID 31420888
Citations 12
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: Turner syndrome (TS) is responsible for gonadal dysgenesis with high risk of premature ovarian insufficiency. Little is known about fertility preservation (FP) strategies is this population.

Design: Data from women with TS consulting with a fertility specialist in our FP centre from 2014 to 2018 were retrospectively collected.

Measurement: Total number of mature oocytes cryopreserved using vitrification.

Patients: Nine women with TS were referred. Three women with different karyotypes underwent controlled ovarian stimulation (COS) for oocyte vitrification. Mean age at TS diagnosis was 13.7 years [9-20]. Mean referral delay between TS diagnosis and fertility consultation was 9.7 years [7-14]. First counselling for FP was provided at 23.7 years [18-28]. Mean AMH serum level prior to COS was 53.8 pmol/L [3.6-95].

Results: All three women succeeded in obtaining cryopreserved oocytes with a mean number of 15.3 per woman [9-20] and 9.2 per COS cycle [2-20]. Ovarian response to COS was unexpectedly remarkable for the woman with a complete 45,X monosomy. Procedure was well tolerated for all women. None of them have used oocytes for in vitro fertilization yet.

Conclusions: Independently of karyotype, antral follicular count, AMH and FSH levels seemed to be reliable predictive markers of oocyte cryopreservation success. In a monosomic TS woman, cryptic ovarian mosaicism could explain a successful ovarian response to stimulation with a high number of retrieved oocytes. In case of spontaneous menarche, TS adolescents should be referred during transition to adulthood for FP counselling to avoid referral delay and limit time-related diminished ovarian reserve.

Citing Articles

Clinical practice guidelines for the care of girls and women with Turner syndrome.

Gravholt C, Andersen N, Christin-Maitre S, Davis S, Duijnhouwer A, Gawlik A Eur J Endocrinol. 2024; 190(6):G53-G151.

PMID: 38748847 PMC: 11759048. DOI: 10.1093/ejendo/lvae050.


Navigating fertility dilemmas across the lifespan in girls with Turner syndrome-a scoping review.

van der Coelen S, van der Velden J, Nadesapillai S, Braat D, Peek R, Fleischer K Hum Reprod Update. 2024; 30(4):383-409.

PMID: 38452347 PMC: 11215162. DOI: 10.1093/humupd/dmae005.


Transition from pediatric to adult care in patients with Turner syndrome in Italy: a consensus statement by the TRAMITI project.

Aversa T, De Sanctis L, Faienza M, Gambineri A, Balducci A, DAprile R J Endocrinol Invest. 2024; 47(7):1585-1598.

PMID: 38376731 PMC: 11196323. DOI: 10.1007/s40618-024-02315-4.


Oocyte cryopreservation in mosaic Turner syndrome with polycystic ovaries.

Sienko A, Prakash A, MacDougall J F S Rep. 2024; 4(4):380-383.

PMID: 38204943 PMC: 10774874. DOI: 10.1016/j.xfre.2023.10.001.


Anti-Müllerian hormone beyond an ovarian reserve marker: the relationship with the physiology and pathology in the life-long follicle development.

Iwase A, Hasegawa Y, Tsukui Y, Kobayashi M, Hiraishi H, Nakazato T Front Endocrinol (Lausanne). 2023; 14:1273966.

PMID: 38027144 PMC: 10657644. DOI: 10.3389/fendo.2023.1273966.